HM15421/GC1134A could become the first subcutaneous enzyme replacement therapy for Fabry disease, with BioMarin paying $70 million upfront.
|Articles|February 13, 2020
MilliporeSigma and ReForm Collaborate on Excipient Commercialization
Author(s)BioPharm International Editors
The companies have entered into a global licensing and collaboration agreement to commercialize ReForm excipients used in biotherapeutic formulations.
Advertisement
MilliporeSigma and ReForm Biologics, a formulation innovation company based in Woburn, MA, announced on Feb. 10, 2020 that they have entered into a global licensing and collaboration agreement to commercialize ReForm excipients used in biotherapeutic formulations.
Through the agreement, MilliporeSigma will handle the research, development, global commercialization, GMP manufacturing, and sale of the excipients, and ReForm will collect revenues from MilliporeSigma for sublicensing their technology to MilliporeSigma’s biologic formulations, according to a ReForm press release.
“MilliporeSigma is a global leader in providing pharmaceutical excipients for biologic formulation. This agreement will make ReForm Biologics’ excipients available through their GMP manufacturing and distribution network, accelerate our research and development activities, and greatly expand our presence in biological drug development,” said John M. Sorvillo PhD, CEO, ReForm, in the press release. “As more biologics are being developed to treat a broad range of diseases ranging from cancer to orphan indications, we believe there will be a growing demand for new excipients that can enhance the patient experience, improve patient outcomes, and potentially extend the patent life of a therapeutic.”
Source:
Advertisement
Related to this article
DAX-044 aims to confine IL-12 activity to tumors and avoid the toxicity that has limited IL-12 therapy, with phase 1 testing expected in 2027.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Boehringer Ingelheim will pay Sino Biopharmaceutical $358 million upfront and near-term for options on six biologic oncology programs, deepening a partnership that began in 2024.
Teva will commercialize etanercept-ykro (Eticovo) and infliximab-abda, adding 2 TNF inhibitor biosimilars to US options for inflammatory diseases.
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
Advertisement
Advertisement
Trending on BioPharm International
1
Policy Leaders Urge Treasury to Narrow Biotech Outbound Investment Rule
2
Shilpa CDMO Commits $50 Million to Scale Peptide Capacity in India
3
Spyre’s Anti-TL1A Antibody SPY072 Misses in Psoriatic Arthritis and Axial Spondyloarthritis, Shifts Focus to Hidradenitis Suppurativa
4
Boehringer Ingelheim Licenses Six Preclinical ADC and T-Cell Engager Programs From SBP Group in Deal Worth Up to $7 Billion
5